ALIVUS LIFE SCIENCES Financial Statement Analysis
|
||
|
The Revenues of ALIVUS LIFE SCIENCES have increased by 5.64% YoY .
The Earnings Per Share (EPS) of ALIVUS LIFE SCIENCES has increased by 0.84 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ALIVUS LIFE SCIENCES Last 5 Annual Financial Results
[BOM: 543322|NSE : ALIVUS]
| Standalone | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹2,283 Cr | ₹2,161 Cr | ₹2,123 Cr | ₹1,885 Cr | ₹1,537 Cr |
| Expenses | ₹1,609 Cr | ₹1,519 Cr | ₹1,507 Cr | ₹1,294 Cr | ₹1,065 Cr |
| Operating Profit (Excl OI) | ₹674 Cr | ₹642 Cr | ₹616 Cr | ₹591 Cr | ₹472 Cr |
| Other Income | ₹12 Cr | ₹29 Cr | ₹15 Cr | ₹0.81 Cr | ₹12 Cr |
| Interest | ₹1.55 Cr | ₹0.55 Cr | ₹28 Cr | ₹88 Cr | ₹34 Cr |
| Depreciation | ₹53 Cr | ₹42 Cr | ₹38 Cr | ₹33 Cr | ₹29 Cr |
| Profit Before Tax | ₹631 Cr | ₹629 Cr | ₹565 Cr | ₹471 Cr | ₹421 Cr |
| Profit After Tax | ₹471 Cr | ₹467 Cr | ₹419 Cr | ₹352 Cr | ₹313 Cr |
| Earnings Per Share (Rs) | ₹38.43 | ₹38.11 | ₹34.17 | ₹358.76 | ₹1,597.44 |
| PAT Margin (%) | 20.56 | 21.49 | 19.70 | 18.60 | 20.34 |
| ROE(%) | 21.15 | 22.33 | 29.87 | 60.91 | 127.84 |
| ROCE(%) | 28.31 | 30.01 | 42.24 | 96.75 | 185.60 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 12,273.3 Cr |
| Revenue (TTM) | : | ₹ 2,273.9 Cr |
| Net Profit(TTM) | : | ₹ 441.7 Cr |
| EPS (TTM) | : | ₹ 36.1 |
| P/E (TTM) | : | 27.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ALIVUS LIFE SCIENCES | -0.2% | 13.9% | 35.2% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.3% | 11.7% | 5.1% |
| DIVIS LABORATORIES | -1.6% | 4% | 58.7% |
| CIPLA | 0.8% | 6.2% | -2.9% |
| TORRENT PHARMACEUTICALS | 0.7% | 9.8% | 19.8% |
| DR REDDYS LABORATORIES | -1% | 2.8% | -8% |
| MANKIND PHARMA | -1.4% | 4.5% | 4.7% |
| ZYDUS LIFESCIENCES | 1.1% | 3.5% | -10.8% |
| LUPIN | 3.7% | 7.3% | 23.8% |
ALIVUS LIFE SCIENCES Revenues
[BOM: 543322|NSE : ALIVUS]
| Y-o-Y | 5.64 % |
| 5 Yr CAGR | 10.39 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹2,283 Cr | 5.64 | |
| Mar2023 | ₹2,161 Cr | 1.79 | |
| Mar2022 | ₹2,123 Cr | 12.63 | |
| Mar2021 | ₹1,885 Cr | 22.63 | |
| Mar2020 | ₹1,537 Cr | - | |
ALIVUS LIFE SCIENCES Operating Profit
[BOM: 543322|NSE : ALIVUS]
| Y-o-Y | 4.97 % |
| 5 Yr CAGR | 9.33 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹674 Cr | 4.97 | |
| Mar2023 | ₹642 Cr | 4.26 | |
| Mar2022 | ₹616 Cr | 4.23 | |
| Mar2021 | ₹591 Cr | 25.24 | |
| Mar2020 | ₹472 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -0.64 % |
| 5 Yr CAGR | -0.97 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 29.53% | -0.64 | |
| Mar2023 | 29.72% | 2.41 | |
| Mar2022 | 29.02% | -7.43 | |
| Mar2021 | 31.35% | 2.12 | |
| Mar2020 | 30.7% | - | |
ALIVUS LIFE SCIENCES Profit After Tax
[BOM: 543322|NSE : ALIVUS]
| Y-o-Y | 0.84 % |
| 5 Yr CAGR | 10.74 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹471 Cr | 0.84 | |
| Mar2023 | ₹467 Cr | 11.52 | |
| Mar2022 | ₹419 Cr | 19.10 | |
| Mar2021 | ₹352 Cr | 12.29 | |
| Mar2020 | ₹313 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -4.33 % |
| 5 Yr CAGR | 0.27 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 20.56 % | -4.33 | |
| Mar2023 | 21.49 % | 9.09 | |
| Mar2022 | 19.7 % | 5.91 | |
| Mar2021 | 18.6 % | -8.55 | |
| Mar2020 | 20.34 % | - | |
ALIVUS LIFE SCIENCES Earnings Per Share (EPS)
[BOM: 543322|NSE : ALIVUS]
| Y-o-Y | 0.84 % |
| 5 Yr CAGR | -60.62 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹38 | 0.84 | |
| Mar2023 | ₹38 | 11.53 | |
| Mar2022 | ₹34 | -90.48 | |
| Mar2021 | ₹359 | -77.54 | |
| Mar2020 | ₹1,597 | - | |
ALIVUS LIFE SCIENCES Return on Capital Employed (ROCE)
[BOM: 543322|NSE : ALIVUS]
| Y-o-Y | -5.66 % |
| 5 Yr CAGR | -37.51 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 28.31% | -5.66 | |
| Mar2023 | 30.01% | -28.95 | |
| Mar2022 | 42.24% | -56.34 | |
| Mar2021 | 96.75% | -47.87 | |
| Mar2020 | 185.6% | - | |
ALIVUS LIFE SCIENCES Share Price vs Sensex
| Current Share Price | : | ₹1,001.9 |
| Current MarketCap | : | ₹ 12,273.3 Cr |
| Updated EOD on | : | Apr 04,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALIVUS LIFE SCIENCES | -0.2% |
13.9% |
35.2% |
| SENSEX | -2.9% |
3.1% |
1.8% |
ALIVUS LIFE SCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE MIDSMALLCAP | 1.4% | 9.3% | 8.2% |
| BSE ALLCAP | -0.8% | 4.8% | 5.8% |
| BSE SMALLCAP | -2% | 7.2% | 3.2% |
| BSE HEALTHCARE | -2.3% | 5.7% | 14.3% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 250 | -2.2% | 7.5% | 0.1% |
| NIFTY 500 EQUAL WEIGHT | -2.4% | 6.4% | NA |
| NIFTY MIDSMALLCAP 400 | -2.5% | 5.9% | 2.1% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | -2.6% | 5.4% | NA |
| NIFTY500 MULTICAP 50:25:25 | -2.7% | 5.1% | 1.8% |
You may also like the below Video Courses
FAQ about ALIVUS LIFE SCIENCES Financials
How the annual revenues of ALIVUS LIFE SCIENCES have changed ?
The Revenues of ALIVUS LIFE SCIENCES have increased by 5.64% YoY .
How the Earnings per Share (EPS) of ALIVUS LIFE SCIENCES have changed?
The Earnings Per Share (EPS) of ALIVUS LIFE SCIENCES has increased by 0.84 % YoY .
Check out Intrinsic Value of Peers of ALIVUS LIFE SCIENCES
Compare Stock Analytics of Peers of ALIVUS LIFE SCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
